UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 31, 2005
BrainStorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Washington 333-61610 912061053
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
1350 Avenue of the Americas
New York, NY 10019
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 212-557-9000
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02(D) APPOINTMENT OF NEW DIRECTORS
On March 31, 2005 our Board of Directors increased its size from three to four
directors and appointed Dr. Robert Shorr to serve as director. A copy of the
press release announcing Dr. Shorr's appointment is attached hereto as Exhibit
99.1.
Since 2000, Dr. Shorr, age 51, has served as President and CEO of Cornerstone
Pharmaceuticals Inc., a bio-technology company. From 1998 he has also served as
Director of Business Development at the State University of New York's Stony
Brook Center for Advanced Technology. From 1998 until 2002 he was Vice-President
of Science and Technology (CSO) of United Therapeutics Corp., a NASDAQ listed
bio-technology company. From 1999 Dr. Shorr has served as trustee at the Tissue
Engineering Charities of the Imperial College of Science and Technology in
London. Prior to 1998 he held management positions at Enzon Inc., a NASDAQ
listed bio-technology company, and AT Biochem of which he was also founder. Dr.
Shorr also serves on the Board of Directors of Biological Delivery Systems Inc.
and Pluristem Life Systems Inc. Dr. Shorr holds both a Ph.D and a D.I.C from the
Imperial College of Science and Technology in London as well as a BSc. from the
State University of New York.
Dr. Shorr is not a party to any transaction, or series of transactions, required
to be disclosed pursuant to Item 404 of Regulation S-B.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press release dated March 31, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: April 4, 2005
BRAINSTORM CELL THERAPEUTICS INC.
/s/ Yaffa Beck
------------------------------
Name: Yaffa Beck
Title: President & CEO
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
99.1 Press release dated March 31, 2005